144 related articles for article (PubMed ID: 34168564)
21. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
[TBL] [Abstract][Full Text] [Related]
22. [Multi-criteria decision analysis in clinical comprehensive evaluation of Chinese patent medicine].
Dai ZQ; Xu SM; Wu X; Li MM; Hu J; Liao X
Zhongguo Zhong Yao Za Zhi; 2022 Jun; 47(12):3155-3160. PubMed ID: 35851106
[TBL] [Abstract][Full Text] [Related]
23. Ranking Decision-Making Criteria for Early Adoption of Innovative Surgical Technologies.
Shoman H; Almeida ND; Tanzer M
JAMA Netw Open; 2023 Nov; 6(11):e2343703. PubMed ID: 37971741
[TBL] [Abstract][Full Text] [Related]
24. Using multicriteria decision analysis during drug development to predict reimbursement decisions.
Williams P; Mauskopf J; Lebiecki J; Kilburg A
J Mark Access Health Policy; 2014; 2(1):25270. PubMed ID: 29785248
[TBL] [Abstract][Full Text] [Related]
25. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
26. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
27. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
Angelis A; Montibeller G; Hochhauser D; Kanavos P
BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
[TBL] [Abstract][Full Text] [Related]
28. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
29. Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses.
Jakab I; Németh B; Elezbawy B; Karadayı MA; Tozan H; Aydın S; Shen J; Kaló Z
Front Pharmacol; 2020; 11():1203. PubMed ID: 32922287
[TBL] [Abstract][Full Text] [Related]
30. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
31. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
Coghlan R; Stephens P; Mwale B; Siyanga M
Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
[TBL] [Abstract][Full Text] [Related]
32. Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United States.
Wagner M; Samaha D; Khoury H; O'Neil WM; Lavoie L; Bennetts L; Badgley D; Gabriel S; Berthon A; Dolan J; Kulke MH; Goetghebeur M
Adv Ther; 2018 Jan; 35(1):81-99. PubMed ID: 29270780
[TBL] [Abstract][Full Text] [Related]
33. Need for multicriteria evaluation of generic drug policies.
Kaló Z; Holtorf AP; Alfonso-Cristancho R; Shen J; Ágh T; Inotai A; Brixner D
Value Health; 2015 Mar; 18(2):346-51. PubMed ID: 25773570
[TBL] [Abstract][Full Text] [Related]
34. A novel drug selection decision support model based on real-world medical data by the hybrid entropic weight TOPSIS method.
Lu J; Wang G; Ying X; Li Z
Technol Health Care; 2023; 31(2):691-703. PubMed ID: 36278366
[TBL] [Abstract][Full Text] [Related]
35. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.
Goetghebeur MM; Wagner M; Khoury H; Rindress D; Grégoire JP; Deal C
Cost Eff Resour Alloc; 2010 Apr; 8():4. PubMed ID: 20377888
[TBL] [Abstract][Full Text] [Related]
36. Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.
Baltussen R; Marsh K; Thokala P; Diaby V; Castro H; Cleemput I; Garau M; Iskrov G; Olyaeemanesh A; Mirelman A; Mobinizadeh M; Morton A; Tringali M; van Til J; Valentim J; Wagner M; Youngkong S; Zah V; Toll A; Jansen M; Bijlmakers L; Oortwijn W; Broekhuizen H
Value Health; 2019 Nov; 22(11):1283-1288. PubMed ID: 31708065
[TBL] [Abstract][Full Text] [Related]
37. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.
Hoshikawa K; Ono S
J Clin Pharm Ther; 2017 Feb; 42(1):80-86. PubMed ID: 27914099
[TBL] [Abstract][Full Text] [Related]
38. Development and pilot of a multicriteria decision analysis (MCDA) tool for health services administrators.
Blythe R; Naidoo S; Abbott C; Bryant G; Dines A; Graves N
BMJ Open; 2019 Apr; 9(4):e025752. PubMed ID: 31023757
[TBL] [Abstract][Full Text] [Related]
39. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016.
Drake JI; de Hart JCT; Monleón C; Toro W; Valentim J
J Mark Access Health Policy; 2017; 5(1):1360545. PubMed ID: 29081919
[No Abstract] [Full Text] [Related]
40. Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development.
Kremer IEH; Jongen PJ; Evers SMAA; Hoogervorst ELJ; Verhagen WIM; Hiligsmann M
BMC Med Inform Decis Mak; 2021 Apr; 21(1):123. PubMed ID: 33836742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
